Corton Capital Inc. trimmed its position in Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) by 13.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,400 shares of the company’s stock after selling 1,685 shares during the period. Corton Capital Inc.’s holdings in Kura Oncology were worth $191,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of KURA. Nisa Investment Advisors LLC raised its position in Kura Oncology by 80.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,290 shares of the company’s stock worth $60,000 after buying an additional 1,470 shares during the last quarter. Denali Advisors LLC raised its holdings in Kura Oncology by 71.1% during the second quarter. Denali Advisors LLC now owns 6,500 shares of the company’s stock worth $119,000 after purchasing an additional 2,700 shares in the last quarter. Amalgamated Bank purchased a new stake in Kura Oncology in the 1st quarter valued at approximately $123,000. Principal Financial Group Inc. acquired a new position in Kura Oncology during the 2nd quarter worth approximately $198,000. Finally, Bridgefront Capital LLC purchased a new position in shares of Kura Oncology during the 1st quarter worth approximately $180,000.
Kura Oncology Price Performance
Kura Oncology stock opened at $15.22 on Friday. Kura Oncology, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $19.93. The stock’s fifty day moving average is $15.14 and its two-hundred day moving average is $15.16.
Analysts Set New Price Targets
A number of analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, September 21st. StockNews.com began coverage on shares of Kura Oncology in a research report on Wednesday, October 12th. They set a “sell” rating on the stock. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $38.29.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.
- Get a free copy of the StockNews.com research report on Kura Oncology (KURA)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify’s Downtrend?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.